Strongyloides stercoralis is known to be endemic to tropical and subtropical regions of the world including the Southeastern United States. [1][2][3] Globally, an estimated 100 million people are infected. 4 Chronic strongyloidiasis can lead to hyperinfection and dissemination in the setting of immunosuppression, including after solid organ transplantation (SOT). [5][6][7][8] Disseminated Strongyloides infection has high rates of morbidity and mortality and is frequently complicated by gram-negative sepsis and meningitis. 9 Screening and treatment for strongyloidiasis during the pretransplant evaluation of patients can reduce the risk of post-transplant disseminated infection. 10 Targeted screening based on travel history and country of origin alone, which recent data show, is the standard at most transplant centers in the United States, incompletely identifies at-risk patients. 8 Data on universal screening prior to SOT in non-endemic regions are limited. [11][12][13] We implemented universal serology-based screening for Strongyloides at our transplant center located in New York City, an urban area with a very cosmopolitan population. 14 To the best of our knowledge, this is the first report of the prevalence of strongyloidiasis among solid organ transplant candidates in a non-endemic region.
| MATERIAL S AND ME THODS
| Study populationWe identified all patients age ≥18 years who were referred for heart or lung transplantation at the NYU Langone Transplant Institute